ACP
HLVX

Acuta Capital Partners’s HilleVax HLVX Stock Holding History

Acuta Capital Partners’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-250,609
Closed -$4.17M – 36
2024
Q1 		$4.17M Sell
250,609
-73,991
-23% -$1.18M 2.71% 16
2023
Q4 		$5.21M Buy
324,600
+54,281
+20% +$721K 2.93% 15
2023
Q3 		$3.64M Buy
270,319
+207,241
+329% +$2.92M 2.44% 15
2023
Q2 		$1.08M Buy
63,078
+56,414
+847% +$874K 0.73% 26
2023
Q1 		$110K Buy
+6,664
New +$107K 0.08% 33

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

Acuta Capital Partners's HLVX Position: Q2 2024 in Review

Acuta Capital Partners sold out of HilleVax (HLVX) in Q2 2024, closing a stake of 250,609 shares — an estimated $4.17M sold.

Acuta Capital Partners first reported a position in HLVX in Q1 2023 and held it in 5 quarters. The position peaked at $5.21M in Q4 2023. 93 funds tracked by Wall St. Rank hold HLVX as of Q2 2024.

  • Acuta Capital Partners reported no remaining HilleVax position as of Q2 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 250,609 HilleVax shares in Q2 2024, an estimated $4.17M.
  • Acuta Capital Partners first reported a position in HilleVax in Q1 2023 and held it in 5 quarters.
  • Acuta Capital Partners's HilleVax position peaked at $5.21M in Q4 2023.
  • 93 funds tracked by Wall St. Rank held HilleVax as of Q2 2024.

Based on Acuta Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.